Document Type
Patent
Publication Date
September 2010
Patent Number
7799788
Abstract
Here, the inventors disclose the treatment of imatinib mesylate resistant chronic myelogenous leukemia cells with a cotreatment of vorinostat (SAHA, suberoylanilide hydroxamic acid) and dasatinib, a dual Abl/Src kinase (TK) inhibitor. Combined treatment of cultured human CML and BaF3 cells with vorinostat and dasatinib induced more apoptosis than either agent alone, as well as synergistically induced loss of clonogenic survival, which was associated with greater depletion of Bcr-Abl, p-CrkL and p-STAT5 levels. Co-treatment with dasatinib and vorinostat also attenuated the levels of Bcr-AblE255K and Bcr-AblT315I and induced apoptosis of BaF3 cells with ectopic expression of the mutant forms of Bcr-Abl. Finally, co-treatment of the primary CML cells with vorinostat and dasatinib induced more loss of cell viability and depleted Bcr-Abl or Bcr-AblT315I, p-STAT5 and p-CrkL levels than either agent alone.
Application Number
12/364,009
Recommended Citation
Bhalla, Kapil N. and Lee, Francis Y., "Method of treating chronic myelogenous leukemia cells" (2010). USF Patents. 519.
https://digitalcommons.usf.edu/usf_patents/519
Assignees
University of South Florida
Filing Date
02/02/2009
Primary/U.S. Class
514/252